Find Radgocitabine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 135598-68-4, Tas-109, Radgocitabine, (2r,3s,4s,5r)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile, Tas 109, 00m634hd2v
Molecular Formula
C10H12N4O4
Molecular Weight
252.23  g/mol
InChI Key
DCYBPMFXJCWXNB-JWIUVKOKSA-N
FDA UNII
00M634HD2V

Radgocitabine
Radgocitabine is an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.
1 2D Structure

Radgocitabine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile
2.1.2 InChI
InChI=1S/C10H12N4O4/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17/h1-2,5-6,8-9,15-16H,4H2,(H2,12,13,17)/t5-,6+,8-,9+/m0/s1
2.1.3 InChI Key
DCYBPMFXJCWXNB-JWIUVKOKSA-N
2.1.4 Canonical SMILES
C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)C#N
2.1.5 Isomeric SMILES
C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)C#N
2.2 Other Identifiers
2.2.1 UNII
00M634HD2V
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2'-cyano-2'-deoxyarabinofuranosylcytosine

2. 2'-cyano-2'deoxy-1-beta-d-arabinofuranosylcytosine

2.3.2 Depositor-Supplied Synonyms

1. 135598-68-4

2. Tas-109

3. Radgocitabine

4. (2r,3s,4s,5r)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile

5. Tas 109

6. 00m634hd2v

7. 2'-cyano-2'-deoxy-1-(beta-d-arabinofuranosyl)cytosine

8. (2r,3s,4s,5r)-2-(4-amino-2-oxopyrimidin-1(2h)-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-carbonitrile

9. Unii-00m634hd2v

10. Radgocitabine [who-dd]

11. Radgocitabine [inn]

12. Chembl337450

13. Schembl1006241

14. Dtxsid30159474

15. Chebi:145435

16. Dfp10917

17. Ex-a1611

18. Hy-16445a

19. 4-amino-l-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)- 2(1h)-pyrimidinone

20. Akos030573293

21. Cs-6837

22. Db11667

23. Ns00069241

24. A857813

25. 1-(2-deoxy-2-cyano-beta-d-arabinofuranosyl)cytosine

26. Q27231358

27. 1-(2-c-cyano-2-deoxy-beta-d-arabino-pentofuranosyl) Cytosine

28. 2'-c-cyano-2'-deoxy-1-beta-d-arabino-pentofuranosyl-cytosine

29. 2'-cyano-2'-deoxy-1-(.beta.-d-arabinofuranosyl)cytosine

30. 4-amino-1-(2-cyano-2-deoxy-beta-d-arabinofuranosyl)pyrimidin-2(1h)-one

31. 2(1h)-pyrimidinone, 4-amino-1-(2-cyano-2-deoxy-.beta.-d-arabinofuranosyl)-

32. 4-amino-l-(2-cyano-2-deoxy-.beta.-d-arabinofuranosyl)- 2(1h)-pyrimidinone

33. (2r,3s,4s,5r)-2-(4-amino-2-oxopyrimidin-1(2h)-yl)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-3-carbonitrile

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 252.23 g/mol
Molecular Formula C10H12N4O4
XLogP3-2.4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area132
Heavy Atom Count18
Formal Charge0
Complexity466
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 135598-68-4 / Radgocitabine API manufacturers, exporters & distributors?

Radgocitabine manufacturers, exporters & distributors 1

95

PharmaCompass offers a list of Radgocitabine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Radgocitabine manufacturer or Radgocitabine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Radgocitabine manufacturer or Radgocitabine supplier.

PharmaCompass also assists you with knowing the Radgocitabine API Price utilized in the formulation of products. Radgocitabine API Price is not always fixed or binding as the Radgocitabine Price is obtained through a variety of data sources. The Radgocitabine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Radgocitabine

Synonyms

135598-68-4, Tas-109, (2r,3s,4s,5r)-2-(4-amino-2-oxopyrimidin-1-yl)-4-hydroxy-5-(hydroxymethyl)oxolane-3-carbonitrile, Tas 109, 00m634hd2v, 2'-cyano-2'-deoxy-1-(beta-d-arabinofuranosyl)cytosine

Cas Number

135598-68-4

Unique Ingredient Identifier (UNII)

00M634HD2V

About Radgocitabine

Radgocitabine is an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.

Radgocitabine Manufacturers

A Radgocitabine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Radgocitabine, including repackagers and relabelers. The FDA regulates Radgocitabine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Radgocitabine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Radgocitabine Suppliers

A Radgocitabine supplier is an individual or a company that provides Radgocitabine active pharmaceutical ingredient (API) or Radgocitabine finished formulations upon request. The Radgocitabine suppliers may include Radgocitabine API manufacturers, exporters, distributors and traders.

Radgocitabine GMP

Radgocitabine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Radgocitabine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Radgocitabine GMP manufacturer or Radgocitabine GMP API supplier for your needs.

Radgocitabine CoA

A Radgocitabine CoA (Certificate of Analysis) is a formal document that attests to Radgocitabine's compliance with Radgocitabine specifications and serves as a tool for batch-level quality control.

Radgocitabine CoA mostly includes findings from lab analyses of a specific batch. For each Radgocitabine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Radgocitabine may be tested according to a variety of international standards, such as European Pharmacopoeia (Radgocitabine EP), Radgocitabine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Radgocitabine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty